Evidence, Records, and What We Can Prove
- Harvard University (NIH-funded review): Andrea Baccarelli confirmed “evidence of an association between exposure to acetaminophen during pregnancy and increased incidence of neurodevelopmental disorders in children.”
- Johns Hopkins University: Research tied Tylenol use during pregnancy to elevated risks of autism and ADHD.
- Mount Sinai Hospital: Findings reinforced the call for “precautionary action.”
- International Consensus Statement (2021): Recommended pregnant women minimize exposure by using “the lowest effective dose for the shortest possible time.”
- Cohort Data:Both the Nurses’ Health Study II and Boston Birth Cohort found significant associations between in utero acetaminophen exposure and later autism diagnoses.
This is not fringe speculation. It is data-driven science, reviewed across multiple respected institutions, that now has the full weight of federal recognition.
Insurance Industry Implications
The insurance sector is preparing for turbulence. For decades, autism claims have strained Medicaid budgets, private health carriers, and disability insurers. Trump’s move raises the stakes:
